Federico Centeno

Dr. Federico Centeno

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2014 in JAMA
Verified
Journal Article
Open access
PDF file
TCThe SIGMA Type 2 Diabetes Consortium
The SIGMA Type 2 Diabetes Consortium
KEKarol Estrada
Karol Estrada
IAIngvild Aukrust
Ingvild Aukrust
LBLise Bjørkhaug
Lise Bjørkhaug
NBNoël P. Burtt
Noël P. Burtt
DMDaniel G. MacArthur
Daniel G. MacArthur
The estimated prevalence of type 2 diabetes in Mexican adults was 14.4% in 2006,1 making it one of the leading causes of death in Mexico.2 Based on statistics from 1999-2002, the standardized prevalence of diagnosed diabetes was 10% in Mexican Americans and 5.2% in whites.3 Although environmental factors such as lifestyle and diet likely explain the majority of this health disparity, it was recently found that genetic variants in the gene SLC16A11 (NCBI NC_000017.11) were associated with higher rates of type 2 diabetes in Latinos.4Latinos, defined as persons who trace their origin to Central and South America, and other Spanish cultures, fall on a continuum of Native American and European genetic ancestry.4 Identifying genetic factors associated with type 2 diabetes in Latino populations could increase understanding of its pathophysiology, improve risk prediction, and focus treatment choice based on knowledge of the underlying biology of the disease.

1 June 2017 in Cell
Verified
Journal Article
Closed access
VRVictor Rusu
Victor Rusu
EHEitan Hoch
Eitan Hoch
JMJosep M. Mercader
Josep M. Mercader
DTDanielle E. Tenen
Danielle E. Tenen
MGMelissa Gymrek
Melissa Gymrek
MCMaria L. Cortes
Maria L. Cortes

9 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
JGJulia K. Goodrich
Julia K. Goodrich
MSMoriel Singer-Berk
Moriel Singer-Berk
RSRachel Son
Rachel Son
ASAbigail Sveden
Abigail Sveden
JWJordan Wood
Jordan Wood
MUMiriam S. Udler
Miriam S. Udler
Hundreds of thousands of genetic variants have been reported to cause severe monogenic diseases, but the probability that a variant carrier develops the disease (termed penetrance) is unknown for virtually all of them. Additionally, the clinical utility of common polygenetic variation remains uncertain. Using exome sequencing from 77,184 adult individuals (38,618 multi-ancestral individuals from a type 2 diabetes case-control study and 38,566 participants from the UK Biobank, for whom genotype array data were also available), we apply clinical standard-of-care gene variant curation for eight monogenic metabolic conditions. Rare variants causing monogenic diabetes and dyslipidemias display effect sizes significantly larger than the top 1% of the corresponding polygenic scores. Nevertheless, penetrance estimates for monogenic variant carriers average 60% or lower for most conditions. We assess epidemiologic and genetic factors contributing to risk prediction in monogenic variant carriers, demonstrating that inclusion of polygenic variation significantly improves biomarker estimation for two monogenic dyslipidemias.

24 August 2017 in Diabetes
Verified
Journal Article
Open access
PDF file
JMJosep M. Mercader
Josep M. Mercader
RLRachel G. Liao
Rachel G. Liao
ABAvery D. Bell
Avery D. Bell
ZDZachary Dymek
Zachary Dymek
KEKarol Estrada
Karol Estrada
JFJose C. Florez
Jose C. Florez
Type 2 diabetes (T2D) affects more than 415 million people worldwide, and its costs to the health care system continue to rise. To identify common or rare genetic variation with potential therapeutic implications for T2D, we analyzed and replicated genome-wide protein coding variation in a total of 8,227 individuals with T2D and 12,966 individuals without T2D of Latino descent. We identified a novel genetic variant in the IGF2 gene associated with ∼20% reduced risk for T2D. This variant, which has an allele frequency of 17% in the Mexican population but is rare in Europe, prevents splicing between IGF2 exons 1 and 2. We show in vitro and in human liver and adipose tissue that the variant is associated with a specific, allele-dosage–dependent reduction in the expression of IGF2 isoform 2. In individuals who do not carry the protective allele, expression of IGF2 isoform 2 in adipose is positively correlated with both incidence of T2D and increased plasma glycated hemoglobin in individuals without T2D, providing support that the protective effects are mediated by reductions in IGF2 isoform 2. Broad phenotypic examination of carriers of the protective variant revealed no association with other disease states or impaired reproductive health. These findings suggest that reducing IGF2 isoform 2 expression in relevant tissues has potential as a new therapeutic strategy for T2D, even beyond the Latin American population, with no major adverse effects on health or reproduction.

12 October 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
HGHumberto Garcia-Ortiz
Humberto Garcia-Ortiz
FBFrancisco Barajas-Olmos
Francisco Barajas-Olmos
CCCecilia Contreras-Cubas
Cecilia Contreras-Cubas
MCMiguel Ángel Cid-Soto
Miguel Ángel Cid-Soto
ECEmilio J. Córdova
Emilio J. Córdova
LOLorena Orozco
Lorena Orozco
The genetic makeup of Indigenous populations inhabiting Mexico has been strongly influenced by geography and demographic history. Here, we perform a genome-wide analysis of 716 newly genotyped individuals from 60 of the 68 recognized ethnic groups in Mexico. We show that the genetic structure of these populations is strongly influenced by geography, and our demographic reconstructions suggest a decline in the population size of all tested populations in the last 15–30 generations. We find evidence that Aridoamerican and Mesoamerican populations diverged roughly 4–9.9 ka, around the time when sedentary farming started in Mesoamerica. Comparisons with ancient genomes indicate that the Upward Sun River 1 (USR1) individual is an outgroup to Mexican/South American Indigenous populations, whereas Anzick-1 was more closely related to Mesoamerican/South American populations than to those from Aridoamerica, showing an even more complex history of divergence than recognized so far.

27 May 2010 in Lupus
Verified
Journal Article
Closed access
ECEj Córdova
Ej Córdova
RVR. Velázquez-Cruz
R. Velázquez-Cruz
FCFederico Centeno
Federico Centeno
VBV. Baca
V. Baca
LOLorena Orozco
Lorena Orozco
Systemic lupus erythematosus (SLE) is an autoimmune disease associated with oxidative stress and characterized by chronic inflammation. Kidney malfunction, an aggressive characteristic of this disease, is not present in all affected individuals. The Nrf2-Keap1 pathway is important in protecting against oxidative stress and inflammation. Mouse models and genome-wide scans have suggested NRF2 (Nuclear factor (erythroid-derived 2)-like 2) as a candidate gene for susceptibility to SLE. We therefore investigated whether NRF2 polymorphisms are associated with childhood-onset SLE in a Mexican Mestizo population. Two single nucleotide polymorphisms (SNPs) were genotyped by TaqMan® assays in 362 patients with childhood-onset SLE and 379 controls. We found no significant association between susceptibility to SLE and NRF2 polymorphisms. However, after population stratification by gender, the heterozygous genotype of the -653G/A SNP was significantly associated with nephritis in females only [OR = 1.81, CI (1.04—3.12), p = 0.032]. This association was stronger in females affected with severe nephritis [classes IV—VI; OR = 2.16, CI (1.12—4.15), p = 0.019]. Our results suggest that NRF2 is not associated with susceptibility to childhood-onset SLE, but it could confer a risk for developing kidney malfunction in SLE-affected individuals.